Galderma RelabotulinumtoxinA U.S. FDA Delay
Analysis based on 9 articles · First reported Jul 01, 2026 · Last updated Jul 01, 2026
The delay in the U.S. approval of RelabotulinumtoxinA for Galderma Group is likely to cause a negative short-term impact on Galderma Group's stock price and investor confidence, as the U.S. market is a significant growth opportunity. However, the product's continued approval and launch in other international markets like Europe, the United Kingdom, the Middle East, Asia, and Australia may mitigate some of the negative sentiment.
Galderma Group received a Complete Response Letter (CRL) from the United States — Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for RelabotulinumtoxinA. The CRL cited observations during a manufacturing site inspection and analytical method optimization. While other aspects of the BLA, including safety and efficacy, did not have deficiencies, Galderma Group is now implementing corrective actions and will engage in dialogue with the FDA to resolve the issues. The company plans a rapid response to the CRL, emphasizing that advancing RelabotulinumtoxinA in the United States remains a top priority. This regulatory setback does not affect approvals, launches, or reviews in other international markets, where Relfydess (RelabotulinumtoxinA) is already approved in 33 markets and launched in over 20, including Europe, the United Kingdom, the Middle East, Asia, and Australia.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard